Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

Recent & Breaking News (NDAQ:RGNX)

REGENXBIO Announces Pricing of Public Offering of Common Stock

GlobeNewswire March 21, 2017

REGENXBIO Announces Proposed Public Offering of Common Stock

GlobeNewswire March 21, 2017

REGENXBIO Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights

GlobeNewswire March 7, 2017

REGENXBIO Announces Initiation of Phase I/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia

GlobeNewswire March 7, 2017

REGENXBIO to Present at the Cowen and Company 37th Annual Health Care Conference

GlobeNewswire March 6, 2017

REGENXBIO to Host Conference Call on March 7 to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights

GlobeNewswire February 28, 2017

REGENXBIO Honors Rare Disease Day® 2017

GlobeNewswire February 28, 2017

REGENXBIO Announces IND Active for Phase I Trial of RGX-314 to Treat Wet Age-Related Macular Degeneration

GlobeNewswire February 14, 2017

REGENXBIO to Present at the 6th Annual LEERINK Partners Global Healthcare Conference

GlobeNewswire February 9, 2017

REGENXBIO to Participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day

GlobeNewswire February 2, 2017

REGENXBIO Provides Year-End 2016 Corporate Update

GlobeNewswire January 6, 2017

REGENXBIO and Voyager Therapeutics Announce Exercise of Options for Rights to NAV Vectors

GlobeNewswire November 29, 2016

Voyager Therapeutics and REGENXBIO Announce Exercise of Options for Rights to NAV Vectors

GlobeNewswire November 29, 2016

REGENXBIO to Present at the 28th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 17, 2016

REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights

GlobeNewswire November 9, 2016

REGENXBIO to Host Conference Call on November 9 to Discuss Third Quarter 2016 Financial Results and Recent Operational Highlights

GlobeNewswire November 2, 2016

REGENXBIO to Present at the Jefferies Gene Editing and Gene Therapy Summit

GlobeNewswire October 4, 2016

REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV® Gene Therapy in Neurodegenerative Diseases

GlobeNewswire September 13, 2016

REGENXBIO to Participate in Global Healthcare Conferences

GlobeNewswire September 7, 2016

Daniel Tassé Appointed to REGENXBIO Board of Directors

GlobeNewswire August 16, 2016